Gea A Holtman1, Yvonne Lisman-van Leeuwen1, Andrew S Day2,3, Ulrika L Fagerberg4,5, Paul Henderson6,7, Stevan T Leach8, Gøri Perminow9, David Mack10, Patrick F van Rheenen11, Els van de Vijver12, David C Wilson6,7, Johannes B Reitsma13, Marjolein Y Berger1. 1. Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 2. Department of Paediatric Gastroenterology, Sydney Children's Hospital, Randwick, Australia. 3. University of Otago (Christchurch), Christchurch, New Zealand. 4. Centre for Clinical Research, Department of Paediatrics, Västmanlands Hospital, Västerås, Sweden. 5. Karolinska Institutet, Stockholm, Sweden. 6. Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, Scotland. 7. Child Life and Health, University of Edinburgh, Edinburgh, Scotland. 8. School of Women's and Children's Health, Sydney Children's Hospital, Randwick, Australia. 9. Department of Paediatrics, Oslo University Hospital, Oslo, Norway. 10. Deparment of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada. 11. Department of Paediatric Gastroenterology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands. 12. Department of Paediatric Gastroenterology, Antwerp University Hospital, Edegem, Belgium. 13. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Abstract
Importance: Blood markers and fecal calprotectin are used in the diagnostic workup for inflammatory bowel disease (IBD) in pediatric patients. Any added diagnostic value of these laboratory markers remains unclear. Objective: To determine whether adding laboratory markers to evaluation of signs and symptoms improves accuracy when diagnosing pediatric IBD. Data Sources: A literature search of MEDLINE and EMBASE from inception through September 26, 2016. Studies were identified using indexing terms and free-text words related to child, target condition IBD, and diagnostic accuracy. Study Selection: Two reviewers independently selected studies evaluating the diagnostic accuracy of more than 1 blood marker or fecal calprotectin for IBD, confirmed by endoscopy and histopathology or clinical follow-up, in pediatric patients with chronic gastrointestinal symptoms. Studies that included healthy controls and/or patients with known IBD were excluded. Data Extraction and Synthesis: Individual patient data from each eligible study were requested from the authors. In addition, 2 reviewers independently assessed quality with Quality Assessment of Diagnostic Accuracy Studies-2. Mean Outcomes and Measures: Laboratory markers were added as a single test to a basic prediction model based on symptoms. Outcome measures were improvement of discrimination by adding markers as a single test and improvement of risk classification of pediatric patients by adding the best marker. Results: Of the 16 eligible studies, authors of 8 studies (n = 1120 patients) provided their data sets. All blood markers and fecal calprotectin individually significantly improved the discrimination between pediatric patients with and those without IBD, when added to evaluation of symptoms. The best marker-fecal calprotectin-improved the area under the curve of symptoms by 0.26 (95% CI, 0.21-0.31). The second best marker-erythrocyte sedimentation rate-improved the area under the curve of symptoms by 0.16 (95% CI, 0.11-0.21). When fecal calprotectin was added to the model, the proportion of patients without IBD correctly classified as low risk of IBD increased from 33% to 91%. The proportion of patients with IBD incorrectly classified as low risk of IBD decreased from 16% to 9%. The proportion of the total number of patients assigned to the intermediate-risk category decreased from 55% to 6%. Conclusions and Relevance: In a hospital setting, fecal calprotectin added the most diagnostic value to symptoms compared with blood markers. Adding fecal calprotectin to the diagnostic workup of pediatric patients with symptoms suggestive of IBD considerably decreased the number of patients in the group in whom challenges in clinical decision making are most prevalent.
Importance: Blood markers and fecal calprotectin are used in the diagnostic workup for inflammatory bowel disease (IBD) in pediatric patients. Any added diagnostic value of these laboratory markers remains unclear. Objective: To determine whether adding laboratory markers to evaluation of signs and symptoms improves accuracy when diagnosing pediatric IBD. Data Sources: A literature search of MEDLINE and EMBASE from inception through September 26, 2016. Studies were identified using indexing terms and free-text words related to child, target condition IBD, and diagnostic accuracy. Study Selection: Two reviewers independently selected studies evaluating the diagnostic accuracy of more than 1 blood marker or fecal calprotectin for IBD, confirmed by endoscopy and histopathology or clinical follow-up, in pediatric patients with chronic gastrointestinal symptoms. Studies that included healthy controls and/or patients with known IBD were excluded. Data Extraction and Synthesis: Individual patient data from each eligible study were requested from the authors. In addition, 2 reviewers independently assessed quality with Quality Assessment of Diagnostic Accuracy Studies-2. Mean Outcomes and Measures: Laboratory markers were added as a single test to a basic prediction model based on symptoms. Outcome measures were improvement of discrimination by adding markers as a single test and improvement of risk classification of pediatric patients by adding the best marker. Results: Of the 16 eligible studies, authors of 8 studies (n = 1120 patients) provided their data sets. All blood markers and fecal calprotectin individually significantly improved the discrimination between pediatric patients with and those without IBD, when added to evaluation of symptoms. The best marker-fecal calprotectin-improved the area under the curve of symptoms by 0.26 (95% CI, 0.21-0.31). The second best marker-erythrocyte sedimentation rate-improved the area under the curve of symptoms by 0.16 (95% CI, 0.11-0.21). When fecal calprotectin was added to the model, the proportion of patients without IBD correctly classified as low risk of IBD increased from 33% to 91%. The proportion of patients with IBD incorrectly classified as low risk of IBD decreased from 16% to 9%. The proportion of the total number of patients assigned to the intermediate-risk category decreased from 55% to 6%. Conclusions and Relevance: In a hospital setting, fecal calprotectin added the most diagnostic value to symptoms compared with blood markers. Adding fecal calprotectin to the diagnostic workup of pediatric patients with symptoms suggestive of IBD considerably decreased the number of patients in the group in whom challenges in clinical decision making are most prevalent.
Authors: Els Van de Vijver; Andrea Bertilde Schreuder; Wybrich Riemke Cnossen; Anna Caecilia Muller Kobold; Patrick Ferry van Rheenen Journal: Arch Dis Child Date: 2012-09-27 Impact factor: 3.791
Authors: Sara Ashorn; Teemu Honkanen; Kaija-Leena Kolho; Merja Ashorn; Tuuli Välineva; Bo Wei; Jonathan Braun; Immo Rantala; Tiina Luukkaala; Sari Iltanen Journal: Inflamm Bowel Dis Date: 2009-02 Impact factor: 5.325
Authors: Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Anke Heida; Els Van de Vijver; Don van Ravenzwaaij; Stephanie Van Biervliet; Thalia Z Hummel; Zehre Yuksel; Gieneke Gonera-de Jong; Renate Schulenberg; Anneke Muller Kobold; Patrick Ferry van Rheenen Journal: Arch Dis Child Date: 2018-03-07 Impact factor: 3.791
Authors: Martina Orfei; Marco Gasparetto; Kai O Hensel; Florian Zellweger; Robert B Heuschkel; Matthias Zilbauer Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Marta Velasco Rodríguez-Belvís; Javier Francisco Viada Bris; Carmen Plata Fernández; Alberto García-Salido; Julia Asensio Antón; Gloria Domínguez Ortega; Rosa Ana Muñoz Codoceo Journal: Paediatr Child Health Date: 2019-06-17 Impact factor: 2.253